Losartan to prevent hyperenzymemia after endoscopic retrograde cholangiopan-creatography: A randomized clinical trial

doi:10.4253/wjge.v4.i11.506

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 11

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3942)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

380

HTML

2825

Figures (1-1)

492

Tables (1-3)

245

Sum=3942

Nov 16, 2012 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Endoscopy

ISSN

1948-5190

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastrointest Endosc. Nov 16, 2012; 4(11): 506-512
Published online Nov 16, 2012. doi: 10.4253/wjge.v4.i11.506

Full Size Figure Download Figure

Figure 1 Flowchart of the patients who underwent endoscopic retrograde cholangio-pancreatography and were considered for inclusion in the study. DIC: Disseminated intravascular coagulation; ECRP: Endoscopic retrograde cholangiopancreatography; ARB: Angiotensin II receptor blockers; ACE: Angiotensin I converting enzyme.

Citation: Bexelius TS, Blomberg J, Lu YX, Håkansson HO, Möller P, Nordgren CE, Arnelo U, Lagergren J, Lindblad M. Losartan to prevent hyperenzymemia after endoscopic retrograde cholangiopan-creatography: A randomized clinical trial. World J Gastrointest Endosc 2012; 4(11): 506-512
URL: https://www.wjgnet.com/1948-5190/full/v4/i11/506.htm
DOI: https://dx.doi.org/10.4253/wjge.v4.i11.506